WHO IARC Talc Probably Carcinogenic Group 2A

IARC Talc Classification — Key Data
Classification Date	July 4, 2024
IARC Group	2A — "Probably Carcinogenic"
Monograph	Volume 136
Prior Classification	Group 2B ("Possibly Carcinogenic")
Expert Panel	29 international scientists
Scope	All forms of talc
Products Affected	Baby powder, cosmetics, industrial
US Regulatory Status	No mandatory testing
EU Regulatory Status	Ban expected 2027
Pending US Lawsuits	67,115 in MDL 2738
2025 Verdict Total	$2.5+ billion
Largest Single Verdict	$1.5B (Craft v. J&J, Dec 2025)
FDA Contamination Rate	15% of products (2018–2022)

Executive Summary

On July 4, 2024, the World Health Organization's International Agency for Research on Cancer (IARC) formally upgraded talc from Group 2B ("possibly carcinogenic") to Group 2A ("probably carcinogenic to humans") through Monograph Volume 136. A working group of 29 international scientists reviewed the totality of epidemiological, animal, and mechanistic evidence and concluded that the carcinogenic hazard applies to all forms of talc — asbestos-containing and asbestos-free alike. Group 2A is the second-highest cancer-risk designation in the IARC system, below only Group 1 ("known carcinogen"), which includes asbestos, tobacco smoke, and benzene.

The scientific foundation for the reclassification rests on peer-reviewed research demonstrating direct links between cosmetic talc exposure and mesothelioma. A landmark 2023 study published in the Journal of Occupational and Environmental Medicine documented 166 mesothelioma patients with confirmed cosmetic talc exposure, of whom 73.5% had no other identifiable asbestos source. FDA testing of cosmetic talc products from 2018 through 2022 detected asbestos in 15% of samples, confirming that consumer products on household shelves contained known carcinogens during the period when exposure claims arose.

The IARC reclassification has accelerated an already massive litigation wave. As of March 2026, 67,115 cases remain pending in MDL 2738 against Johnson & Johnson. Talc verdicts in 2025 alone exceeded $2.5 billion, including a $1.5 billion single-plaintiff verdict in Craft v. Johnson & Johnson (Baltimore, December 2025) — the largest award in individual talc litigation history — and a $966 million verdict in Moore v. Johnson & Johnson (Los Angeles, October 2025). Johnson & Johnson's three attempts to discharge talc liability through subsidiary bankruptcy filings have all been rejected by federal courts.

Regulatory response has been uneven. The European Union classified talc as a Category 1B carcinogen and plans to ban talc in cosmetics by 2027. In the United States, the FDA withdrew a proposed mandatory asbestos testing rule for cosmetic talc in November 2025, removing the primary federal safeguard that would have required pre-market contamination screening. No mandatory federal testing requirement for asbestos in cosmetic talc currently exists.

At-a-Glance

WHO/IARC Talc Classification at a glance:

• IARC upgraded talc to Group 2A ("probably carcinogenic to humans") in July 2024 via Monograph Volume 136, following review by 29 international experts
• All forms of talc carry the Group 2A classification — not just asbestos-contaminated varieties
• Group 2A is the second-highest IARC carcinogen tier, behind only Group 1 (asbestos, tobacco, benzene)
• 166 mesothelioma patients with cosmetic talc exposure were documented by Moline et al. (2023); 73.5% had no other asbestos source
• 15% of cosmetic talc products tested by the FDA between 2018 and 2022 contained asbestos
• 67,115 lawsuits are pending in MDL 2738 as of March 2026, with total filings exceeding 90,000
• $2.5 billion+ in talc verdicts were awarded in 2025 alone
• $1.5 billion single-plaintiff verdict in Craft v. J&J (December 2025) is the largest in talc litigation history
• Johnson & Johnson's three bankruptcy attempts to limit talc liability have all been rejected by federal courts
• EU plans to ban talc in cosmetics by 2027; the United States has no mandatory testing requirement after FDA withdrew its proposed rule in November 2025

Key Facts

Measure	Finding (Source)
IARC Classification Date	July 4, 2024 — Monograph Volume 136
IARC Group Assigned	Group 2A — "Probably Carcinogenic to Humans"
Evidence Basis	Limited human evidence + sufficient animal evidence + strong mechanistic evidence
Previous Classification	Group 2B — "Possibly Carcinogenic to Humans"
Expert Panel	29 international scientists convened by IARC/WHO
Scope	All forms of talc (not limited to asbestos-contaminated talc)
Key Epidemiological Finding	73.5% of 166 mesothelioma patients with talc exposure had no other asbestos source — Moline et al. 2023
FDA Contamination Rate	Asbestos found in 15% of cosmetic talc products tested 2018–2022
MDL 2738 Pending Cases	67,115 as of March 2026
Largest 2025 Verdict	$1.5 billion — Craft v. J&J, Baltimore, December 2025 (peritoneal mesothelioma)
J&J Bankruptcy Attempts	3 — all rejected by federal courts (2021, 2023, 2024–2025)
EU Regulatory Action	Talc classified as Category 1B carcinogen; ban in cosmetics expected 2027

What Is the IARC Carcinogen Classification System?

The International Agency for Research on Cancer (IARC) is the specialized cancer research agency of the World Health Organization, headquartered in Lyon, France. IARC evaluates substances, mixtures, and exposures for their potential to cause cancer in humans using a four-tier classification system based on the strength of available scientific evidence.

Group 1 — "Carcinogenic to humans": The highest certainty level. Sufficient evidence from human studies demonstrates that the agent causes cancer. Group 1 agents include asbestos, tobacco smoke, benzene, and formaldehyde. Asbestos-contaminated talc was already Group 1 by extension, because asbestos itself is a known carcinogen.

Group 2A — "Probably carcinogenic to humans": The second-highest certainty level. Evidence of carcinogenicity in humans is "almost sufficient" under IARC's 2019 Preamble. This designation requires either limited evidence in humans combined with sufficient evidence in animals, or strong mechanistic evidence supporting carcinogenicity. Other Group 2A substances include glyphosate (the active ingredient in Roundup, which has generated billions in litigation settlements) and red meat. Talc received this classification in July 2024.

Group 2B — "Possibly carcinogenic to humans": A lower evidentiary threshold than 2A. Requires limited evidence in humans or sufficient evidence in animals but not both in combination with mechanistic evidence. Talc previously held this classification.

Group 3 — "Not classifiable as to its carcinogenicity to humans": Inadequate evidence in humans and inadequate or limited evidence in animals. This does not mean the substance is safe — only that the evidence is insufficient for classification.

Feature	Group 1 (Asbestos)	Group 2A (Talc, 2024)
Classification	"Carcinogenic to humans"	"Probably carcinogenic to humans"
Human Evidence	Sufficient	Limited
Animal Evidence	Sufficient	Sufficient
Mechanistic Evidence	Strong	Strong
Examples	Asbestos, tobacco smoke, benzene	Talc, glyphosate, red meat
Certainty Level	Highest	Second-highest

The distinction between "limited" and "sufficient" evidence in humans is frequently misunderstood. "Limited evidence" does not mean absence of evidence — it means that multiple epidemiological studies show an association between the agent and cancer, but the association cannot be ruled out as resulting from confounding factors, bias, or chance. For talc, human studies consistently showed elevated cancer risk in exposed populations, but the working group determined that confounders could not be fully excluded, placing the human evidence at "limited" rather than "sufficient."

How Did IARC Reclassify Talc from Group 2B to Group 2A in 2024?

Prior to July 2024, IARC maintained separate classifications for talc based on asbestos content. Talc containing asbestiform fibers was effectively classified as Group 1 by extension, because asbestos itself is a known human carcinogen. Non-asbestiform talc — talc without detectable asbestos — was classified as Group 2B ("possibly carcinogenic") based on the limited body of evidence available at the time of earlier evaluations.

The July 4, 2024 publication of Monograph Volume 136 superseded these separate classifications entirely. The working group of 29 international scientists conducted a multi-year review and evaluated talc as a single substance regardless of asbestos content. Three independent evidence streams supported the upgrade:

Limited evidence for cancer in humans: Multiple cohort and case-control studies documented elevated mesothelioma and ovarian cancer risk in individuals with cosmetic talc exposure who had no occupational asbestos history. The Moline et al. 2023 study identified 166 mesothelioma patients with confirmed cosmetic talc exposure, 73.5% of whom had no other identifiable asbestos source. An earlier 2020 study by the same research group documented mesothelioma cases "attributable to the presence of anthophyllite and tremolite asbestos" in talc products.

Sufficient evidence for cancer in experimental animals: The National Toxicology Program (NTP) found that non-asbestiform, cosmetic-grade talc caused lung tumors in female rats and adrenal gland tumors (pheochromocytomas) in both male and female rats at high doses. Additional animal studies confirmed carcinogenic potential across multiple experimental models.

Strong mechanistic evidence: Talc particles exhibit key characteristics of carcinogens in human primary cells and experimental systems, including chronic inflammation, oxidative stress, and cellular disruption. These biological changes promote carcinogenesis independent of asbestos fiber content. The IARC working group found that talc reached Group 2A through all three classification scenarios described in its framework — a convergence that reinforced the strength of the overall evidence.

The reclassification carries a critical distinction: Group 2A applies to all forms of talc. The old separation between asbestos-containing talc (Group 1 by extension) and "pure" talc (Group 2B) no longer exists in the IARC framework. This means talc itself — independent of asbestos contamination — is now recognized as probably carcinogenic to humans.

Why Does Talc Deposit Geology Matter?

Talc is a hydrated magnesium silicate mineral (Mg₃Si₄O₁₀(OH)₂) that forms during the metamorphism of magnesian minerals. Asbestos minerals — including tremolite, anthophyllite, and chrysotile — share overlapping metamorphic formation conditions with talc, which is why they frequently co-occur in the same geological deposits. Understanding this geological relationship is essential to evaluating contamination risk in mined talc products.

A landmark 2004 USGS study by Van Gosen et al. established that the talc-forming environment directly predicts its asbestos contamination risk:

• Hydrothermal talcs (formed by replacement of dolostone): Consistently lack amphiboles as accessory minerals — lowest contamination risk
• Contact metamorphic talcs: Show a strong tendency to contain amphiboles, including asbestiform varieties
• Regional metamorphic talcs: Consistently contain amphiboles displaying a variety of compositions and habits, including asbestiform fibers

Region	Deposit Type	Asbestos Types Found
Gouverneur, NY (USA)	Regional metamorphic	Tremolite, anthophyllite, asbestiform talc
Val Chisone, Italy	Regional metamorphic	Tremolite
Vermont (USA)	Regional metamorphic	Tremolite (0.05%)
Death Valley, CA (USA)	Contact metamorphic	Tremolite, richterite, winchite (up to 1%)
Rajasthan, India	Various	Tremolite (7 of 13 products positive)
Gebel El Maiyit, Egypt	Ultramafic-hosted	Anthophyllite, asbestiform talc

The practical consequence of this geological relationship is that complete separation of talc from asbestos during mining and milling is technically impossible for many deposit types. Dr. Rodney Metcalf of the University of Nevada testified before Congress that "Talc and amphibole asbestos minerals can and certainly do co-exist at scales that cannot be mined in such a way as to exclude amphibole minerals." Johnson & Johnson's own internal documents acknowledged that "asbestos-form particles" could not be completely removed from talc ore.

The sensitivity of detection methods for asbestos in talc varies by orders of magnitude, and the industry's reliance on less sensitive methods has been a central issue in litigation:

Method	Detection Limit	Strengths	Limitations
PLM (Polarized Light Microscopy)	~100 ppm (~0.01%)	Quick, inexpensive	Cannot detect fine chrysotile fibers
XRD (X-Ray Diffraction)	~5,000 ppm (0.5%)	Identifies crystal structure	Cannot distinguish fibrous from non-fibrous; misses chrysotile entirely
TEM (Transmission Electron Microscopy)	~0.000002%	Most sensitive; identifies fiber type	Expensive, time-consuming
SEM-EDS	Sub-micron resolution	High-resolution imaging with elemental analysis	Requires specialized equipment

The cosmetic talc industry adopted the CTFA J4-1 method in 1976, which used XRD with a detection limit of only 0.5% for amphibole asbestos and did not test for chrysotile at all. As recently as 2019, the FDA found chrysotile asbestos in Johnson's Baby Powder that had passed both the J4-1 method and J&J's own proprietary TEM method, demonstrating that "asbestos-free" certification based on industry testing standards was unreliable.

What Products Contain Talc and How Are Consumers Exposed?

Talc-containing consumer and industrial products fall into three broad categories, each with distinct exposure pathways relevant to mesothelioma risk.

Baby powder and body powder: Johnson's Baby Powder was the most widely used talc-based consumer product for decades. Gordon et al. (2014) demonstrated that one historic brand of cosmetic talcum powder contained asbestos, that application of the powder released inhalable asbestos fibers, and that lung and lymph node tissues from a deceased user contained anthophyllite and tremolite asbestos consistent with talc contamination. In October 2019, J&J recalled approximately 33,000 bottles of Baby Powder after FDA testing found chrysotile asbestos in one sample. J&J discontinued talc-based Baby Powder in the United States and Canada in 2020 and globally in 2023.

Cosmetics: The FDA's 2019 survey tested 52 talc-containing cosmetic products and found asbestos in 9 of them (17% contamination rate), including Claire's JoJo Siwa Makeup Set marketed to young girls, multiple Claire's eye shadows and compact powders, and several BeautyPlus brand products. All contaminated Claire's products were recalled. Between 2018 and 2022, the overall contamination rate across FDA testing was approximately 15%.

Industrial uses: According to the USGS Mineral Commodity Summary for 2025, worldwide talc mine production was approximately 6,900 thousand metric tons in 2024. In the United States, talc is used primarily in plastics (32%), ceramics (21%), paint (18%), paper (9%), roofing (8%), and rubber (6%). Workers in these industries face ongoing occupational inhalation exposure to talc dust.

Exposure routes: Inhalation during product application is the primary route — talc powder becomes airborne when applied to the body, releasing fibers that can be inhaled deep into lung tissue. Peritoneal exposure occurs when talc applied to the perineal area migrates through the reproductive tract to the peritoneal surface via retrograde transport. This pathway explains the elevated proportion of peritoneal mesothelioma (31.3%) observed in the Moline 2023 cosmetic talc study — more than double the 10–15% rate in the general mesothelioma population. Occupational exposure affects cosmetologists, barbers, healthcare workers, and industrial talc workers who handle the mineral daily.

How Have the United States and EU Responded to the Talc Classification?

United States

The Modernization of Cosmetics Regulation Act (MoCRA) of 2022 explicitly mandated the FDA develop standardized testing methods for asbestos in talc-containing cosmetics. On December 26, 2024, the FDA proposed a rule that would have required manufacturers to test every batch of talc cosmetics using polarized light microscopy (PLM) and transmission electron microscopy (TEM). Any detectable level of asbestos would have rendered a product adulterated under the FD&C Act.

The proposed rule was itself already one year behind MoCRA's statutory deadline of December 2023. On November 28, 2025, HHS Secretary Robert F. Kennedy Jr. officially withdrew the proposed rule, citing "Make America Healthy Again (MAHA) priorities" and the need to "reconsider best means of addressing the issues." The withdrawal removed the primary federal safeguard that would have required pre-market contamination screening of cosmetic talc products, leaving a significant regulatory gap:

• No mandatory federal testing requirement exists for asbestos in cosmetic talc
• Testing remains entirely voluntary — cosmetic companies self-regulate
• The FDA's statutory obligation under MoCRA to establish testing standards still exists, but no replacement rule has been proposed and no timeline given
• The EPA finalized a comprehensive asbestos ban in 2024 under the Toxic Substances Control Act (TSCA), but the current administration has signaled it will reconsider that ban

European Union

The EU has moved in the opposite direction. The European Chemicals Agency's (ECHA) Committee for Risk Assessment classified talc as a Category 1B carcinogen in September 2024, based on studies linking talc to lung tumors in female rats and ovarian tumors in humans. Under EU law, substances classified as CMR 1B face automatic prohibition in cosmetics under Annex II of Regulation (EC) No. 1223/2009. A ban on talc in cosmetics in the EU is expected by 2027.

Country/Region	Current Status	Key Action
United States	No mandatory testing	FDA withdrew proposed rule Nov 2025
European Union	Ban expected 2027	ECHA RAC classified talc as Category 1B (Sept 2024)
United Kingdom	Under review	HSE assessment ongoing; diverging from EU
India	Minimal regulation	Major producer; 7 of 13 products tested positive for asbestos

What Is the Johnson & Johnson Talc Litigation Timeline?

Johnson & Johnson faces the largest active mass tort in the United States federal court system. As of March 2026, 67,115 cases are pending in MDL 2738 in the District of New Jersey before Judge Michael Shipp, with total filings exceeding 90,000.

The litigation has produced a series of landmark verdicts that accelerated after the 2024 IARC reclassification. In 2025 alone, talc verdicts exceeded $2.5 billion in aggregate award value.

Date	Case / Jurisdiction	Award	Cancer Type
Dec 2025	Craft v. J&J — Baltimore, MD	$1.5 billion	Peritoneal mesothelioma
Dec 2025	Minnesota	$65.5 million	Mesothelioma
Oct 2025	Moore v. J&J — Los Angeles, CA	$966 million	Mesothelioma
Jul 2025	Boston, MA	$42 million	Mesothelioma
Jun 2025	Suffolk County, MA	$8 million	Mesothelioma
2024	Multiple jurisdictions (cumulative)	$320 million+	Mesothelioma
Jun 2023	Lee v. J&J — Portland, OR	$260 million	Mesothelioma
2023	Prudencio — San Jose, CA	$26.5 million	Mesothelioma (childhood exposure)
2018	Anderson v. J&J — California	$25.7 million	Mesothelioma
Jul 2018	Ingham v. J&J — St. Louis, MO (22 plaintiffs)	$4.69 billion	Ovarian cancer

The Texas Two-Step Bankruptcy Strategy: Johnson & Johnson attempted three times to use subsidiary bankruptcy filings to channel all talc liabilities into a trust fund and halt civil litigation:

1. October 2021: J&J created LTL Management LLC, transferred all talc liabilities, and LTL filed Chapter 11. The Third Circuit dismissed the case — LTL was not in genuine "financial distress" given J&J's $61.5 billion funding commitment.
2. 2023: Second attempt through LTL, also dismissed by U.S. Bankruptcy Judge Michael Kaplan.
3. September 2024: J&J created Red River Talc LLC, filed Chapter 11, proposed an $8 billion settlement fund. Judge Christopher Lopez rejected the plan in March 2025. J&J announced it would not appeal and would "return to the tort system."

With all bankruptcy options exhausted, the full litigation pipeline remains open. The MDL case count grew from 58,205 in early 2025 to 67,115 by February 2026 — an increase of nearly 9,400 cases in one year.

Which Other Companies Face Talc Litigation?

Johnson & Johnson is the primary but not the sole defendant in talc litigation. Multiple talc suppliers, distributors, and product manufacturers face legal liability.

Imerys Talc America: The world's largest talc supplier and historically J&J's sole supplier for cosmetic talc products. Imerys filed for Chapter 11 bankruptcy in 2019 after facing thousands of asbestos and talc lawsuits. The company proposed a $1.45 billion trust fund to compensate claimants. In January 2024, Imerys and former owner Cyprus Mines proposed a joint $862 million trust fund. In 2025, the U.S. District Court for the District of Delaware affirmed the Bankruptcy Court's order in In re Imerys Talc America (Case No. 1:2024cv01232, D. Del.). As of 2026, bankruptcy proceedings continued as insurance companies challenged the trust plan.

R.T. Vanderbilt / Vanderbilt Minerals: Mined industrial-grade tremolitic talc from the Gouverneur district in upstate New York, where deposits are regional metamorphic in origin and consistently contain tremolite and anthophyllite asbestos. Vanderbilt filed for bankruptcy in February 2026, citing $117.2 million in talc-related indemnity and defense costs from more than 1,400 lawsuits. A 2024 Connecticut jury awarded $15 million to the family of Nicholas Barone, who died from mesothelioma linked to Vanderbilt's talc.

Colgate-Palmolive: Faces 170+ active talc lawsuits related to its Cashmere Bouquet talcum powder product line, sold from the late 1800s through 1995. In 2015, a California jury found Colgate 95% responsible for a woman's mesothelioma and awarded $12.4 million; Colgate settled before the punitive damages phase. In 2024, Colgate settled the Carol Schoeniger mesothelioma lawsuit (Pennsylvania plaintiff) in a New Jersey courtroom for an undisclosed amount. The company has resolved more than 43 cases in a single year through settlements. In the October 2025 Moore v. Johnson & Johnson trial in Los Angeles, Colgate-Palmolive, Avon Products, Chanel Inc., and Revlon Inc. were named as nonparty companies; the jury found all four not negligent in that specific case, while awarding $966 million against J&J.

Whittaker, Clark & Daniels: A talc supplier that filed for Chapter 11 bankruptcy in April 2023 after a South Carolina jury ordered it to pay $29.14 million to a 36-year-old woman who developed mesothelioma from asbestos-contaminated talc supplied to Mary Kay and Johnson & Johnson. More than 2,700 individuals had sued the company by that point.

Defendant	Role	Bankruptcy Status	Key Liability
Johnson & Johnson	Product manufacturer	3 failed attempts	$7B+ in verdicts; 67,115 pending
Imerys Talc America	Talc supplier/miner	Chapter 11 (2019)	$1.45B proposed trust
Cyprus Mines	Talc supplier	Bankruptcy (2021)	Joint $862M trust with Imerys
Vanderbilt Minerals	Talc miner	Chapter 11 (Feb 2026)	$117.2M in costs; 1,400+ lawsuits
Whittaker Clark & Daniels	Talc supplier	Chapter 11 (2023)	$29.14M verdict; 2,700+ lawsuits
Colgate-Palmolive	Product manufacturer	Not bankrupt	170+ lawsuits; $12.4M verdict; 43+ settlements
Avon / Revlon / Chanel	Product manufacturers	Revlon: Ch. 11 (June 2022)	Named in talc litigation; found not negligent in Moore v. J&J (Oct 2025)

How Does Global Talc Mining Affect Asbestos Exposure Risk?

The scale and geography of global talc production are directly relevant to contamination risk because the geological setting of each mining region determines whether its talc carries co-occurring asbestos fibers.

Global Production

Worldwide talc mine production totaled approximately 6,900 thousand metric tons in 2024. China is the world's largest producer, followed by India and the United States. In the U.S., three companies operated five talc-producing mines in three states (Montana, Texas, and Vermont) during 2024, with domestic crude production of 530,000 tons valued at approximately $27 million. Principal U.S. import sources include Canada, China, and Pakistan, with imports decreasing approximately 11% in 2024 compared to the prior year.

U.S. talc consumption by end-use sector breaks down as: plastics (32%), ceramics (21%), paint (18%), paper (9%), roofing (8%), and rubber (6%). The cosmetic and pharmaceutical sectors represent a smaller volume share but carry the highest public health significance because these products are applied directly to the body.

Deposit Type and Contamination Risk

As the Van Gosen USGS study established, the geological formation process predicts whether a deposit contains amphibole asbestos (see geology section above). This has direct implications for global sourcing: talc from hydrothermal deposits (common in Montana, USA) carries the lowest contamination risk, while regional metamorphic deposits — such as those in the Gouverneur district of New York, Val Chisone in Italy, and parts of Rajasthan, India — consistently contain tremolite and anthophyllite asbestos.

Testing of Indian consumer products has revealed the scope of the problem: 7 of 13 talc products tested from Rajasthan-sourced talc contained tremolite asbestos fibers. India is one of the world's largest talc producers and exporters, and its deposits span multiple geological types with varying contamination profiles.

Industry Response to the 2024 IARC Reclassification

The IARC Group 2A reclassification has intensified pressure on the global talc supply chain. Johnson & Johnson had already ceased global sales of talc-based baby powder in 2023, before the reclassification. The EU's classification of talc as a Category 1B carcinogen — with a cosmetics ban expected by 2027 — is forcing European manufacturers to reformulate products or source alternative minerals. In contrast, the United Kingdom diverged from the EU in January 2026, with the UK Health and Safety Executive concluding there was "not enough evidence to label talc a carcinogen" under GB CLP regulations.

The regulatory divergence between the EU ban, the UK exemption, and the U.S. regulatory gap means that talc products banned in Europe may continue to be sold in the United States and United Kingdom. For consumers and workers, exposure risk now depends not only on the geological source of the talc but also on which regulatory jurisdiction governs the product.

What Legal Rights Do Talc Exposure Victims Have?

Individuals diagnosed with mesothelioma after exposure to cosmetic talc products have multiple compensation pathways available, regardless of whether they had any occupational asbestos exposure.

Who qualifies: Any person diagnosed with mesothelioma (pleural, peritoneal, or pericardial) who has a documented history of using talc-containing products — including baby powder, body powder, or cosmetic products — may have grounds for legal action. The Moline et al. 2023 study documented that 73.5% of cosmetic talc mesothelioma patients had no other known asbestos exposure, establishing that consumer product exposure alone is sufficient to cause the disease.

Civil lawsuits: Personal injury and wrongful death lawsuits can be filed against product manufacturers (Johnson & Johnson, Colgate-Palmolive), talc suppliers (Imerys, Vanderbilt), and other parties in the supply chain. Verdicts in talc mesothelioma cases have ranged from $8 million to $1.5 billion. Legal experts estimate average individual talc settlement values at approximately $500,000.

Asbestos trust fund claims: Multiple talc-related defendants have established or proposed bankruptcy trust funds. The Imerys trust proposes $1.45 billion; a joint Imerys-Cyprus Mines trust proposes $862 million. Trust fund claims can be filed simultaneously with civil lawsuits without one reducing the other. The asbestos trust fund system holds more than $30 billion for victims of asbestos exposure across 60+ active trusts.

Statute of limitations: Filing deadlines vary by state and generally begin from the date of diagnosis — not the date of exposure. Given mesothelioma's latency period of 20–50 years, many current cases involve exposure from decades past. Consulting a mesothelioma attorney promptly after diagnosis is critical to preserve filing rights. The state-by-state filing deadlines determine the window available for each claim.

Frequently Asked Questions

What does the WHO IARC Group 2A classification of talc mean?

The Group 2A classification means IARC's expert working group concluded talc is "probably carcinogenic to humans" — the second-highest certainty level in the IARC system. This July 2024 decision, published as Monograph Volume 136, upgraded talc from Group 2B ("possibly carcinogenic") after 29 international scientists reviewed epidemiological, animal, and mechanistic evidence. The classification applies to all forms of talc, including talc not containing detectable asbestos fibers.

Is talc the same as asbestos?

No. Talc (Mg₃Si₄O₁₀(OH)₂) and asbestos minerals are chemically and structurally distinct. However, they frequently co-occur in the same geological deposits because they form under similar metamorphic conditions. The IARC Group 2A classification applies to talc itself, separate from asbestos — meaning talc may be carcinogenic independent of asbestos contamination. The practical challenge is that many commercially mined talc deposits contain trace to measurable amounts of tremolite, anthophyllite, or chrysotile asbestos that cannot be fully removed during processing.

Can talc products cause mesothelioma without asbestos contamination?

IARC's 2024 Group 2A classification suggests yes — the evidence basis included mechanistic evidence that talc exhibits key characteristics of carcinogens independent of asbestos fiber content. However, the majority of documented mesothelioma cases involving talc products also involved asbestos-contaminated talc. The Moline et al. 2023 study found that 73.5% of 166 cosmetic talc mesothelioma patients had no other known asbestos exposure source, though the talc products they used may have contained undetected asbestos.

How many people have sued Johnson & Johnson over talc?

As of March 2026, 67,115 lawsuits are pending in the talc MDL (MDL 2738) in the District of New Jersey, with total filings exceeding 90,000. Johnson & Johnson's three bankruptcy attempts to resolve these claims through subsidiary trust funds were all rejected by federal courts. The most recent rejection came in March 2025, after which J&J announced it would not appeal.

Are talc products still on the market?

Yes. Johnson & Johnson discontinued talc-based baby powder globally in 2023, but other brands continue to sell talc-containing cosmetics in the United States. The FDA withdrew its proposed mandatory asbestos testing rule in November 2025, meaning no federal testing requirement currently exists — testing is entirely voluntary. The EU plans to ban talc in all cosmetics by 2027, which will force reformulation for any brand selling in European markets.

What is the largest talc cancer verdict?

The largest single-plaintiff talc verdict is $1.5 billion, awarded in Craft v. Johnson & Johnson in Baltimore in December 2025, involving peritoneal mesothelioma ($59.84 million compensatory plus punitive damages). The largest aggregate verdict is $4.69 billion (reduced to $2.12 billion on appeal in 2020) awarded to 22 plaintiffs in St. Louis in 2018 for ovarian cancer. Total talc verdicts in 2025 exceeded $2.5 billion.

Did the FDA ban talc?

No. The FDA proposed a rule in December 2024 requiring mandatory asbestos testing in cosmetic talc products, as required by the Modernization of Cosmetics Regulation Act (MoCRA) of 2022. HHS Secretary Robert F. Kennedy Jr. withdrew that proposed rule on November 28, 2025, citing MAHA priorities. The FDA's statutory obligation under MoCRA to establish testing standards still exists, but no replacement rule has been proposed and no timeline has been given. Currently, no mandatory federal talc testing standard exists in the United States.

Quick Statistics

• Group 2A — IARC classification for talc as of July 2024: "probably carcinogenic to humans"
• $2.5 billion+ — Total talc verdict value in 2025 alone
• $1.5 billion — Craft v. J&J (Baltimore, December 2025), largest single-plaintiff talc verdict
• $966 million — Moore v. J&J (Los Angeles, October 2025)
• 67,115 — Pending cases in MDL 2738 as of March 2026
• 90,000+ — Total talc lawsuits filed to date against Johnson & Johnson
• 73.5% — Moline 2023 mesothelioma patients with talc exposure and no other asbestos source
• 15% — FDA asbestos contamination rate in cosmetic talc products, 2018–2022
• 166 — Mesothelioma patients with documented cosmetic talc exposure in Moline 2023
• 2027 — Year EU plans to ban talc in cosmetics

Get Help

Individuals diagnosed with mesothelioma or ovarian cancer following talc product exposure have legal options. The IARC Group 2A reclassification and the 2025 verdict record demonstrate that courts hold manufacturers accountable when evidence supports causation.

Danziger & De Llano is a mesothelioma law firm with experience in talc litigation. The firm represents clients in MDL 2738 and in state court talc cases nationwide. Consultations are free, and cases are handled on contingency — no fees unless there is a recovery. Contact: dandell.com

To find qualified mesothelioma attorneys near your location: mesotheliomalawyersnearme.com

Time limits apply in all talc cases. Statutes of limitation vary by state and begin running from the date of diagnosis. Do not delay in seeking a legal evaluation.

Related Pages

• Mesothelioma Overview
• Asbestos Health Effects
• Asbestos Trust Funds
• Mesothelioma Lawyers
• Asbestos Fiber Types and Potency
• Secondary Asbestos Exposure